← All companies
Mirum Pharmaceuticals, Inc.
MIRM - CIK 0001759425
Market cap$5.73 B
Rank#1294
SEC filings612
Mirum Pharmaceuticals, Inc. trades as MIRM and has a market capitalization of $5.73 B, making it the #1294 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $521.31M, up 54.7% from the prior year and net income of -$23.36M. This page tracks Mirum Pharmaceuticals, Inc. through 612 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$521.31MFY 2025
Net income (latest FY)-$23.36MFY 2025
Operating cash flow (latest FY)$55.83MFY 2025
Total assets (latest FY)$842.81MFY 2025
Net margin-4.5%latest FY
Financial performance
Net profit margin expanded from -438.9% to -4.5% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $5.73 B
- Share price (derived)market cap / shares outstanding
- $94.00
- EPS (diluted)FY 2025
- $-0.47
- Shares outstandingas of 2026-05-01
- 0.06B
- Total equityas of 2026-03-31
- $242.49M
- Return on equity
- -9.6%
- Cash & equivalentsas of 2026-03-31
- $324.91M
- Current ratioas of 2026-03-31
- 2.09
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Major company event | 8-K | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G/A | - | 2026-04-27 |
| Major company event | 8-K | 2026-04-27 |
Recent press releases
- Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 20262026-05-21
_\- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)_
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-14
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
- Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering2026-05-12
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Mirum also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $90.0 million aggregate principal amount of notes.
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Similar companies
The largest companies sharing Mirum Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is Mirum Pharmaceuticals, Inc.'s market cap?
Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of $5.73 B as of 2026-06-10, ranking #1294 among US-listed companies.
How much revenue does Mirum Pharmaceuticals, Inc. make?
Mirum Pharmaceuticals, Inc. reported revenue of $521.31M for fiscal year 2025, an increase of 54.7% year over year.
Is Mirum Pharmaceuticals, Inc. profitable?
In its latest fiscal year Mirum Pharmaceuticals, Inc. reported a net loss of $23.36M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.